Vor Biopharma Stock (NASDAQ:VOR)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.90

52W Range

$0.63 - $3.14

50D Avg

$0.81

200D Avg

$1.35

Market Cap

$59.33M

Avg Vol (3M)

$1.00M

Beta

-0.41

Div Yield

-

VOR Company Profile


Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

168

IPO Date

Feb 05, 2021

Website

VOR Performance


VOR Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-126.04M$-93.42M$-69.02M
Net Income$-117.86M$-90.77M$-68.78M
EBITDA$-122.54M$-90.89M$-67.58M
Basic EPS$-1.75$-2.29$-2.06
Diluted EPS$-1.75$-2.29$-2.06

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
NUVLNuvalent, Inc.
NRIXNurix Therapeutics, Inc.
KYMRKymera Therapeutics, Inc.
TALSTourmaline Bio, Inc.
CGEMCullinan Oncology, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
FHTXFoghorn Therapeutics Inc.
DAWNDay One Biopharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
ERASErasca, Inc.
BOLTBolt Biotherapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
ACLXArcellx, Inc.
DSGNDesign Therapeutics, Inc.
AUTLAutolus Therapeutics plc
ACETAdicet Bio, Inc.
LYRALyra Therapeutics, Inc.
STTKShattuck Labs, Inc.